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Breast cancer (BC) is a heterogeneous disease that
exhibits familial aggregation. Family linkage studies
have identiﬁed high-penetrance genes, BRCA1, BRCA2,
PTEN and TP53, that are responsible for inherited BC
syndromes. Moreover, a combination of family-based and
population-based approaches indicated that genes involved
in DNA repair, such as CHEK2, ATM, BRIP and
PALB2, are associated with moderate risk. Therefore, all
of these known genes account for only 25% of the familial
aggregation cases. Recently, genome wide association
studies (GWAS) in BC revealed single nucleotide poly-
morphisms (SNPs) in ﬁve novel genes associated to
susceptibility: TNRC9, FGFR2, MAP3K1, H19 and
lymphocyte-speciﬁc protein 1 (LSP1). The most strongly
associated SNP was in intron 2 of the FGFR2 gene that is
ampliﬁed and overexpressed in 5–10% of BC. rs3803662
of TNRC9 gene has been shown to be the SNP with the
strongest association with BC, in particular, this poly-
morphism seems to be correlated with bone metastases
and estrogen receptor positivity. Relevant data indicate
that SNP rs889312 in MAP3K1 is correlated with BC
susceptibility only in BRCA2 mutation carriers, but is not
associated with an increased risk in BRCA1 carriers.
Finally, different SNPs in LSP1 and H19 and in minor
genes probably were associated with BC risk. New
susceptibility allelic variants associated with BC risk were
recently discovered including potential causative genes
involved in regulation of cell cycle, apoptosis, metabolism
and mitochondrial functions. In conclusion, the identiﬁca-
tion of disease susceptibility loci may lead to a better
understanding of the biological mechanism for BC to
improve prevention, early detection and treatment.
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Introduction
Breast cancer (BC) is the most common cancer and the
second leading cause of cancer death among women
(Parkin et al., 2005).
The family history is the main risk factor for BC,
indicating that the genetic factors are very important in the
development of disease (Antoniou and Easton, 2006).
In the 1990s, linkage studies in multiple case families have
identiﬁed two major susceptibility genes in BC BRCA1 and
BRCA2 (Miki et al., 1994; Wooster et al., 1995).
Germline mutations in BRCA1 and BRCA2 genes
occur rarely in the general population but confer high
risks of breast and ovarian cancer and a lower risk for
other cancers (Antoniou et al., 2003; Thompson and
Easton, 2004).
TP53 and PTEN mutations are also present in the
population at low frequency and lead to very high BC
risk associated with rare cancer syndrome, however,
population-based studies have estimated that alterations
in these genes account only the 15% of the familial risk
of BC (Sidransky et al., 1992; FitzGerald et al., 1998;
Peto et al., 1999; Dite et al., 2003).
Further, genetic linkage analyses failed to identify
additional high-penetrance susceptibility genes and the
identiﬁcation of rare variants of genes involved in DNA
repair, such as CHEK2, ATM, BRIP and PALB2 in
families lacking BRCA mutations (Meijers-Heijboer
et al., 2002; Thompson et al., 2005; Rahman et al.,
2007; Hollestelle et al., 2010), associated with a
moderate risk of disease, can explain only a small
portion of familial risk.
Therefore, all of these known genes account for only
25% of the familial aggregation cases (Thompson and
Easton, 2004), suggesting that most of the familial risk
of BC can plausibly involve a combination of multiple
low-penetrance susceptibility alleles, each conferring a
small effect on BC risk (Antoniou and Easton, 2006;
Table 1).
According to this model deﬁned ‘polygenic’, proposed
to explain the genetic susceptibility to BC, a large
number of low-risk variants occurs with high frequency
in populations, therefore, it may have a multiplicative
effect in determining the overall risk of disease (Pharoah
et al., 2002; Figure 1). A signiﬁcant part of polygenic
contribute to low-penetrance susceptibility may rise by
non-conservative missense mutations in evolutionarily
conserved domains.Received 10 July 2011; revised 9 August 2011; accepted 9 August 2011
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Genome-wide association studies (GWAS)
In recent years the research of low-penetrance allelic
variants was conducted mainly through GWAS. These
studies use a large number of common genetic single
nucleotide polymorphisms (SNPs) to identify associa-
tions with disease that rely upon patterns of linkage
disequilibrium (LD) in the human genome (Hirshﬁeld
et al., 2010). The power of GWAS is to evaluate the
association of genetic variants at different loci on
different chromosomes (LD) in large series of cases
versus controls, analyzing a panel of hundred thousand
SNPs simultaneously, to identify new alleles of suscept-
ibility to BC (Orr and Chanock, 2008). In the human
genome has been estimated that there are seven million
of common SNPs that have a minor allele frequency
(m.a.f.), 45% and because recombination occurs in
different hot-spots, the nascent polymorphisms are often
strongly correlated.
These studies therefore provide a powerful tool to
identify novel markers for susceptibility and prognosis
of disease (Peto, 2002; Houlston and Peto, 2004; Easton
and Eeles, 2008). In the GWA studies the accumulation
of a large number of data is crucial. Houlston and Peto,
(2004) have estimated the number of cases required to
identify low-penetrance alleles conferring a relative risk
of two both in an unselected population and in families
with ﬁrst-degree relatives affected. In an unselected
population the identiﬁcation of a susceptibility allele
with a frequency of 5% requires over 800 cases. In the
same population, the identiﬁcation of a susceptibility
allele with a frequency of 1% requires over 3700
unselected cases, whereas about 700 would be enough
if three affected families are selected. Therefore, the
power of association studies can be signiﬁcantly
increased using selected cases with a family history of
cancer because less cases are required to demonstrate the
association with disease (Houlston and Peto, 2004).
The potential of the association studies of cases with a
family history to identify low-penetrance alleles confer-
ring a relative risk of 2 has been demonstrated by the
mutation CHEK2 1100delC in patients with BC. This
variant carried by 1% of the population confers an
increased risk of 1.7-fold. The frequency was not
signiﬁcantly increased in unselected cases (1.4%), but
it was strongly increased in familial cases without
BRCA1 and BRCA2 mutations (5.1%; Meijers-Heijboer
et al., 2002).
In the past years several novel risk alleles for BC were
identiﬁed by four recent GWA studies: Breast Cancer
Association Consortium, Cancer Genetic Markers of
Susceptibility, DeCode Islanda, Memorial Sloan–Ket-
tering Cancer Center (Easton et al., 2007; Hunter et al.,
2007; Gold et al., 2008; Stacey et al., 2008).
In each of them the association study was shared into
three phases: the ﬁrst phase identiﬁes the common SNPs
in cases and controls, the second phase evaluates how
many of the above SNPs are common to a greater
number of cases and controls and, ﬁnally, the third
phase aims to identify new alleles of susceptibility of BC.
Easton et al., in their study, identiﬁed ﬁve indepen-
dent loci associated with increased susceptibility to BC
(Po107). This multistage study involved in the ﬁrst
stage 390 BC cases with a strong family history and
364 controls, and 3990 cases and 3916 controls in the
second stage.
To deﬁne the risk associated with the 30 most
signiﬁcant SNPs, a third stage of the study was
conducted involving 21 860 cases and 22 578 controls
from 22 additional studies in the Breast Cancer
Association Consortium.
These combined analyses allowed to observe that the
SNPs showing a stronger statistical evidence of associa-
tion with an increased familial risk were: rs2981582 lies
in intron 2 of FGFR2, rs12443621 and rs8051542 within
TNRC9, rs889312 lies in a region that containMAP3K1
gene, rs3817198 lies in intron 10 of lymphocyte-speciﬁc
protein 1 (LSP1) and rs2107425 within the H19 gene.
Unlike other BC susceptibility genes previously
identiﬁed that are involved in DNA repair and sex
hormone synthesis, in this work three of the ﬁve loci
reported contain genes involved in regulation of cell
growth and cell signaling (Easton et al., 2007).
Starting from this study of Easton et al., in attempt
to identify further loci associated with BC risk,
Ahmed et al. have genotyped in a third stage further
814 SNPs, involving 3878 cases and 3928 controls from
three studies of the Cancer Genetic Markers of
Susceptibility.













Figure 1 Allelic variants at low frequency tend to be associated
with higher relative risk of BC (for example, BRCA1, BRCA2),
high-frequency allelic variants are associated with lower RR
(for example, FGFR2, LSP1, and so on) conﬁguring an inverse
correlation.
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These analyses allowed to identify three additional
SNPs (rs4973768, rs4132417 and rs6504950) that have
been evaluated in a fourth stage from 27 studies in the
Breast Cancer Association Consortium.
rs4132417 showed no evidence of association in the
fourth stage, it was probably a false positive. rs4973768
showed strong association with age that was higher for
ER-positive than ER-negative disease, moreover there
was no evidence of association with a positive family
history of BC.
Similarly, rs6504950 showed statistical evidence of
association with ER-positive disease and no association
with the family history, and unlike of rs4973768 no
association with the age.
Moreover, in this study additional association ana-
lyses showed that another SNP rs1357245 is located in
the same LD block as rs4973768 in the 3p24 region
(Ahmed et al., 2009). Genotyping the 28 SNPs, known
to be present in this region, in 2301 cases and 2256
controls, it presents a further SNP rs2307032 that was
correlated with both SNPs.
Hunter et al., in a recent work, have identiﬁed alleles
in FGFR2 associated with risk of sporadic postmeno-
pausal BC.
In this study, the National Cancer Institute Cancer
Genetic Markers of Susceptibility identiﬁed four SNPs,
two (rs1219648 and rs2420946) in intron 2 of FGFR2
and two (rs11200014 and rs28981579) in FGFR2 gene,
using GWAS of BC by genotyping 528 173 SNPs in 1145
postmenopausal women of European ancestry with
invasive BC and 1142 controls.
These polymorphic variants showed a strong associa-
tion with the risk of disease (Hunter et al., 2007).
A similar experimental design was conducted by Gold
et al. in 249 Ashkenazi Jewish women, containing multiple
cases of BC but lacking BRCA1 or BRCA2 mutations,
presented at the Memorial Sloan–Kettering Cancer Center.
This study conﬁrmed the BC association with the
FGFR2 locus, identiﬁed by Easton and Hunter studies,
but showed an association with the RNF146 and
ECHDC1 region at 6q22.33 not seen in the previous
works (Gold et al., 2008).
ECHDC1 gene encodes for a trifunctional protein
involved in mitochondrial fatty acid oxidation (Hashimoto
et al., 1996) and RNF146 encodes for a protein, called
actylidin, that functions as a ubiquitin protein ligase
(E3; Mani and Gelmann, 2005), that could have a role in
breast tumorigenesis.
To identify new risk variants associated with BC
susceptibility, Stacey et al. have carried out a GWA
study genotyping 1600 Icelandic individuals with BC
and 11 563 controls.
Two SNPs showed statistically signiﬁcant association
with BC: the A allele of rs13387042 on chromosome
2q35 and the T allele of rs3803662 on 16q12.
The 25% of individuals of European descent are
homozygous for allele A of rs13387042 and have an
estimated 1.44-fold greater risk than noncarriers and
about 7% are homozygous for allele T of rs3803662 and
have a 1.64-fold greater risk.
These risk alleles were not associated with histo-
pathological subtype, stage and grade of tumors, but
confer preferential risk for estrogen receptor (ER)-
positive BC.
In the LD block where lies rs13387042 there are no
known genes, but there are proximally and distally
TNP1, IGFBP5, IGFBP2 and TNS1 genes (Stacey et al.,
2007).
rs3803662 is near the 50 end of TNRC9, whose
increased expression is highly predictive of metastasis
to bone of BC (Smid et al., 2006).
Comparing the results obtained from four major
studies of GWA, it has been highlighted a correlation of
allele frequency of some SNPs located on the genes:
FGFR2 encoding a receptor tyrosine kinase, TNRC9
encoding a high-mobility group chromatin-associated
protein, MAP3K1, which encodes the signaling protein
mitogen-activated protein kinase 1 (MAPK1), LSP1
encoding LSP1 and H19 an untranslated messenger
RNA involved in regulation of the insulin growth factor
gene 2 (Table 2).
These new discovered susceptibility genes are differ-
entially expressed between the ﬁve distinct molecular
subtypes of BC, based on differential gene expression
proﬁles: luminal A, luminal B, basal like, ErbB2þ and
normal like (Sorlie et al., 2003). These distinct molecular
subtypes of BC are associated with different clinical
outcomes (Sorlie et al., 2001).
If the probability to develop a given subtype of BC is
genetically determined, we would expect to ﬁnd that the
Table 2 Comparative analysis of the SNPs identiﬁed in the four studies (BCAC, CGEMS, MSKCC and DeCode Islanda)
Gene Location BCAC CGEMS MSKCC DeCode Islanda
FGFR2 Chr 10q rs2981582
(in intron2)
rs1219648
rs2420946 (in intron2) rs11200014
and rs28981579
rs2981582 No
TNRC9 Chr 16q rs12443621
rs8051542
rs8049226 (within 200 kb of TNRC9) rs3803662 and rs3112625 rs3803662 (near TNRC9)
MAP3K1 Chr 5q rs889312 rs726501 No No
LSP1 Chr 11p rs3817198
rs498337
rs7120258 No No
H19 Chr 11p rs2107425 rs7120258
rs7578974
No No
Abbreviation: BCAC, Breast Cancer Association Consortium; CGEMS, Cancer Genetic Markers of Susceptibility; MSKCC, Memorial Sloan–
Kettering Cancer Center; SNPs, single nucleotide polymorphisms.
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newly discovered susceptibility genes (Easton et al.,
2007) are differentially expressed in the various tumor
subtypes.
Recently a signiﬁcantly differential mRNA expression
of TNRC9, FGFR2,MAP3K1, H19 and LSP1 from 112
breast tumor samples, representing all ﬁve subtypes, has
been identiﬁed by analysis of variance (Nordgard et al.,
2007).
These data show the necessity to conduct stratiﬁed
SNP disease association studies and to select patients by
their molecular subtypes, to confer more power to the
GWA studies.
FGFR2
FGFR2 is a member of a receptor tyrosine kinase gene
superfamily, which contributes to the cell growth,
invasiveness, motility and angiogenesis (Ricol et al.,
1999). Overexpression of FGFR2, one of the common
low-penetrance susceptibility genes, is observed in breast
tumor tissues (Adnane et al., 1991) and in BC cell lines
(Tannheimer et al., 2000). Its expression is associate
with ERþ tumors (Luqmani et al., 1992), suggesting a
hormone-dependent action of this gene. Recently, gene
expression studies have shown increasing FGFR2
expression levels associated with the rare homozygote
genotype and functional studies identiﬁed the OCT1/
RUNX2-binding site as the main determinant of the
increased expression levels (Meyer et al., 2008). Aber-
rant expression of alternatively spliced isoforms of
FGFR2 transforms BC cells by sustained signal
transduction (Moffa and Ethier, 2007). The FGFR2
gene, located at chromosome 10q26, contains at least 22
exons (Ingersoll et al., 2001).
Several mutations and common SNPs within or
ﬂanking the FGFR2 gene have been identiﬁed. A
number of studies have been conducted to investigate
the association between FGFR2 polymorphisms and the
risk of BC in humans. The association is restricted to
SNPs in the LD block covering intron 2. In particular,
three polymorphic variants, rs1219648 (A4G),
rs2420946 (C4T) and rs2981582 (C4T) are more
investigated for their closed correlation with BC. Easton
et al. (2007) showed that rs2981582 had a clear relevance
to BC.
Gold et al. (2008) conﬁrmed the previously reported
results for FGFR2 locus. Recently, a further GWAS
study conﬁrmed the correspondence between FGFR2
susceptibility loci and BC risk. In particular, the per-
allele odds ratio was higher for ER-positive rather than
for ER-negative BC (Ahmed et al., 2009). This ﬁnding is
consistent with the involvement of FGFR2 in estrogen-
related breast carcinogenesis (Tamaru et al., 2004), and
with higher levels of FGFR2 expression in ERþ than
ER cell lines and tumors (Zhang et al., 1999). Stacey
et al. genotyped B300 000 SNPs in 1600 Icelandic
individuals with BC and 11 563 controls. They found
that 25% of individuals of European descent are
homozygous for allele A of rs13387042 on chromosome
2q35 and have an estimated 1.44-fold greater risk than
noncarriers. Risk from both alleles was conﬁned to
ER-positive tumors.
The variant in the 5p12 region, which is close to the
FGFR2 ligand FGF10, also shows strong evidence of an
association primarily with ERþ tumors (Stacey et al.,
2008).
TNRC9
The locus on 16q includes a gene TNRC9 and a
hypothetical gene LOC643714. TNCR9 (also known as
TOX3) is a gene of uncertain function containing a tri-
nucleotide repeat motif and encoding a member of the
high-mobility group family of non-histone chromatin
proteins. The presence of a putative high-mobility group
box motif suggests that it might function as a transcrip-
tion factor (Easton et al., 2007). Several studies have
shown that susceptibility loci at TNCR9 predispose to
sporadic BC. Rs3803662, located near the 50 end of
TNRC9, has been shown to be the SNP with the
strongest association with BC. The SNP rs3803662 is
related to both ERþ and ER tumors (McInerney
et al., 2009).
The associations of rs3803662 with other SNPs seem
to be not signiﬁcant. Other two SNPs (rs12443621 and
rs8051542) with important evidence of association are
located in an LD block containing the 50 end of TNRC9.
Furthermore, Hunter et al. (2007) showed that there is
only one SNP signiﬁcant (rs8049226) within 200 kb of
TNRC9. In contrast, the coding region of TNCR9
contains SNPs showing no evidence of association. The
A allele of rs13387042 located on chromosome 2q35 (A-
rs13387042) and the T allele of rs3803662 on 16q12 (T-
rs3803662) confer increased risk of BC for ER-positive
tumors. Any interaction was observed between the
2q35 and 16q12 loci. Moreover, no known gene or
human RNA was found for the LD block containing
rs13387042. The rs3803662 SNP located on 16q12
occurs in the fourth exon of a poorly characterized
mRNA. In BC, the q arm of chromosome 16 is
frequently lost, therefore, it is likely that one or more
tumor suppressor genes are present in the same region.
Differences in stage, grade or histopathological subtype
were not signiﬁcantly correlated with the low-penetrance
susceptibility alleles, and there was no signiﬁcant
difference in allele frequencies between in situ and
invasive carcinoma. In African Americans, T allele of
the SNP rs3803662 was signiﬁcantly protective and,
thus, it was not associated with increased BC risk
(Stacey et al., 2007). Three susceptibility alleles
(rs2981582, rs3803662 and rs13281615) also have shown
an evidence of association with family history of BC. In
fact, each of these SNPs was more frequent in women
with a ﬁrst-degree relative with the disease than in those
without. Furthermore, an evidence of association with
breast in situ carcinoma has been shown by three SNPs
(rs2981582, rs3803662 and rs889312; Easton et al.,
2007). Increased expression of TNRC9 indicates a major
GWAS in breast cancer
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susceptibility to metastasis of BC to bone. ER positivity
is predictive of bone metastases. The possible effects of
the correlation between rs3803662, TNRC9, bone
metastases and ER positivity remain to be explicated.
Many association studies have shown that SNPs in
FGFR2, TNRC9 and MAP3K1 increase the BC risk in
BRCA2 mutation carriers with a similar relative risk to
that seen in the general population. In contrast, in
BRCA1 mutation carriers only the rs3803662 SNP was
associated with an increased BC risk (Easton and Eeles,
2008).
MAP3K1
MAP3K1 (MEKK1) encodes the MAPK protein that
phosphorylates and activates the MAPK kinase
(MAPK2) that in turn phosphorylates the MAPK/
ERK to produce downstream signaling effects on a
variety of cancer genes. MAP3K1 forms part of the
MAPK cell signaling pathway implicated in cellular
response to mitogens. The MAPK pathway is strongly
linked to HER2 receptor activity and activating muta-
tions in the MAPK pathway have been associated with
HER2þ breast tumors (Bild et al., 2006; Creighton
et al., 2006). MAP3K1 was identiﬁed by Easton et al.
(2007) to have a per-allele odds ratio effect of 1.13 (95%
conﬁdence interval: 1.09–1.18). MAP3K1 effects were
found to be relevant in ERþ and PRþ tumors to a
greater degree than in ER or PR tumors (Garcia-
Closas and Chanock, 2008). MAP3K1 is differentially
expressed in different BC subtypes (Nordgard et al.,
2007). Hunter et al. (2007) found only one SNP
(rs726501) with a P value in the range of Po0.01 by
allele test. Gold in the Memorial Sloan–Kettering
Cancer Center study and Stacey, in the DeCode study,
did not see signiﬁcant SNPs between individuals with
BC and controls. GWA studies conducted by Garcia-
Closas and Chanock identiﬁed that the rs889312 variant
is in a LD block containing the MAP3K (Garcia-Closas
et al., 2008).
The Consortium of Investigators of Modiﬁers of
BRCA1/2 has recently evaluated whether variants in
FGFR2 (rs2981582), TNRC9 (rs3803662) and MAP3K1
(rs889312) are associated with the risk of BC in over
10 000 BRCA1 and BRCA2 mutation carriers from
23 studies (Antoniou et al., 2008). The evidence of
association with SNP rs889312 in MAP3K1 was weaker
and was restricted to BRCA2 mutation carriers, how-
ever, this SNP was not associated with an increased risk
in BRCA1 carriers.
LSP1 and H19
LSP1 gene (also known as WP43) encodes an F-actin
bundling cytoskeletal protein expressed in hematopoie-
tic and endothelial cells. LSP1 has been implicated in
malignant lymphoma and Hodgkin’s disease (Maraﬁoti
et al., 2003), and other variants in this gene have been
associated with risk of developing non-Hodgkin’s
lymphoma (Cerhan et al., 2007). The most important
GWASs reported different conclusion about the role of
LSP1 gene in BC susceptibility. Easton et al. (2007)
reported one SNP (rs3817198) lies in intron 10 of LSP1
gene with P values in the range 105–109; Gold et al.
(2008) found two SNPs (rs3817198, rs498337), near the
LSP1 region, with P values in the range of Po0.01 by
allele test, where Hunter et al. (2007) provided evidence
for one SNP (rs7120258) in the region with a P value
0.01. Recent study identiﬁed that LSP1 minor allele of
rs3817198 was associated with increased BC risk only
for BRCA2 mutation carriers (Antoniou et al., 2009). A
further SNP, rs2107425, located just 110 kb from
rs3817198, was also identiﬁed (overall P¼ 0.00002).
rs2107425 is within the H19 gene, an imprinted
maternally expressed untranslated messenger RNA
closely involved in regulation of the insulin growth
factor gene 2 (Easton et al., 2007). In H19 region on
chromosome 11p, Easton et al. (2007) reported P values
in the range 0.01–105, Gold et al. saw no signal,
whereas Hunter et al. (2007) found two SNPs
(rs7120258, rs7578974), with association P values in
the range of 0.01, with one additional SNP, rs217228,
with a P value in the range of 0.02.
Recently discovered BC susceptibility loci
New susceptibility allelic variants associated with BC
risk were recently discovered through large replication
studies in combination with the original GWAS data.
The combination between these studies and GWAS data
allowed to identify three SNPs: rs4973768, rs4132417
and rs6504950. There is a strong evidence for additional
susceptibility loci on 3p and 17q. The region 3p24
includes two potential causative genes, SLC4A7 and
NEK10. SLC4A7 (solute carrier family 4, sodium
carbonate cotransporter, member 7) is a potential
tyrosine kinase protein whose expression is reduced in
BC specimens and cell lines. NEK10 (never-in mitosis-
related kinase 10) belongs to a family of 11 never in
mitosis a-related kinases that are involved in cell cycle
regulation. However, unlike other NEKs, no role has
been associated to NEK10. A 300-kb LD block on
17q23.2 includes rs6504950 that lies in intron 1 of
STXBP4 (syntaxin-binding protein 4), codifying an
insulin-regulated STX4-binding protein involved in the
regulation of GLUT4 vesicle translocation and glucose
transport. The rs6504950 allelic variant showed no
association with age or family history, but a stronger
association in ER-positive disease versus ER-negative
disease. The same LD block includes other genes as
COX11 (cytocrome C assembly protein 11), that is
located 10 kb upstream of rs6504950, and TOM1L1
(target of myb-1-like1). In lymphocytes, the rs6504950
risk allele is correlated with higher expression of COX11
levels, but no association has been shown with expres-
sion levels of either TOM1L1 or STXBP4. Allele
frequency studies in European populations have
revealed that rs4973768 and rs6504950 could explain
GWAS in breast cancer
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respectively 0.4% and 0.07% of the familial risk of BC.
These susceptibility loci together with those previously
identiﬁed in original GWAS would give rise to 5.9% of
BC familial risk (Ahmed et al., 2009). Further genome-
wide linkage studies have revealed three putative BC
susceptibility regions of interest, located on 3q25, 6q24
and 21q22. Moreover, it has been observed that the
allelic variants on both chromosomes 21 and 3 were
correlated with a higher percentage of bilaterality and a
higher number of familial cases (Rosa-Rosa et al., 2009).
A recent GWAS has identiﬁed a novel polymorphic
variant rs11249433 within the 1p11.2 region associated
with BC risk.
This association is stronger in ER-positive than
ER-negative tumors, is correlated with mRNA expres-
sion of NOTCH2 gene and is highest in breast tumors
without TP53 mutations.
Further studies are needed to evaluate the possible
role of rs11249433 in NOTCH2 regulation and BC
development (Fu et al., 2010). Other variants can
signiﬁcantly modify the BC risk in BRCA1 and BRCA2
mutations carriers. The rs6138178 in SNRPB and
rs6602595 in CAMK1D show a strongest association
in BRCA1 carriers, whereas rs9393597 in LOC134997
and rs12652447 in FBXL7 in BRCA2 carriers.
These loci appeared to interact multiplicatively for BC
risk in BRCA1/BRCA2 carriers, therefore, these SNPs
together with other genetic and environmental factors
may improve the BC risk assessment in these popula-
tions (Wang et al., 2010).
Recently, a new study (Black Women’s Health Study)
has been conducted in a population of African Amer-
ican Women (886 BC cases versus 1089 controls) to
identify genetic variants associated with risk of BC. As
in the original study (Stacey et al., 2008), it has been
conﬁrmed the strong association of rs4415084 on 5p12
with overall risk and ER-positive tumors. No associa-
tion was observed for ER- and PR-negative tumors.
Other susceptibility allelic variants identiﬁed from
BWHS are rs6451770, rs12515012, rs13156930 and
rs16901937. A 21% increase in risk was associated with
each copy of the rs16901937 G-allele. The closest gene to
these regions is MRPS30, involved in apoptosis and
encoding a component of the mitochondrial ribosome.
Moreover, MRPS30 is involved in a gene expression
proﬁle that allows to discriminate ER-positive from ER-
negative tumors (Ruiz-Narvaez et al., 2010). Other BC
susceptibility alleles could be identiﬁed through large-
scale replication studies in combination with previous
GWAS. However, these analyses have still a limited power.
In a recent work, the BC risk association with eight
susceptibility loci identiﬁed by GWAS was investigated
in relation to speciﬁc breast tumor subtypes. A strong
association was identiﬁed between ERþ tumors and six
of eight loci identiﬁed by GWAS: rs2981582 (10q26),
rs3803662 (16q12), rs13281615 (8q24), rs13387042
(2q35), rs4973768 (3p24) and rs6504950 (17q23). A
most strongly relation was observed between two
candidate loci, CASP8 (rs1045485, rs17468277) and
TGFB1 (rs1982073) and PR tumors. Four loci were
associated with triple negative tumors (Pp0.016):
rs3803662 (16q12), rs889312 (5q11), rs3817198 (11p15)
and rs13387042 (2q35) but only two of them (16q12 and
2q35) were associated with tumors with the core basal
phenotype (Pp0.002). This study identifying novel risk
factors associated with BC subtypes could allow a better
tumor stratiﬁcation resulting in prevention, early detec-
tion and treatment improvement (Broeks et al., 2011).
The power of GWAS
The GWAS represents a new powerful approach to
identify lower penetrance alleles that cannot be detected
by genetic linkage studies. The risk conferred by these
alleles individually is too weak, generally 1.3-fold or less,
but the combined effects may be useful for risk
prediction (Easton et al., 2007). This would promote
the development of novel methodologies for analysis of
data generated by large-scale SNP studies. In recent
years, the research and identiﬁcation of low-penetrance
susceptibility loci played a key role in the etiology of BC
and, in particular, of those BCs that have estrogen and
progesterone receptors. The combination of BC suscept-
ibility alleles together with other risk factors may be
important clinically and it may explain an appreciable
fraction of the genetic variance in BC risk. The
identiﬁcation of the causative variants can be extremely
problematic but the use of GWAS from multiple
populations with different patterns of LD can reduce
the difﬁculty of analysis. The power of GWAS may be
increased by enlarging the number of samples in both
the cases and the controls, and by identifying clinical
and molecular subtypes (Kristensen and Borresen-Dale,
2008). However, the GWA experiments need the effort
of several research groups to collect a sufﬁcient number
of patients for large multistage studies and they require
large amounts of money. The allele frequency of the
variant and the risk conferred by it will determine the
number of cases to be genotyped. There is a common
scepticism toward these new approaches because it is not
known the mechanism by which the novel allelic
variants cause the susceptibility. Furthermore, some
differences were found between different studies. This
could be due to population stratiﬁcation, sample-size
differences or genetic heterogeneity in the setting of
different genotyping platforms (Perlegen, Mountain
View, CA, USA; Affymetrix, Santa Clara, CA, USA;
Illumina, San Diego, CA, USA) and different algo-
rithms to ﬁlter data (Gold et al., 2008).
Recently, a novel multi-SNP GWAS analysis method
called Pathways of Distinction Analysis was developed.
This method uses GWAS data and pathway-gene and
gene-SNP associations to identify pathways that could
permit the distinction of cases from controls. Therefore,
relating a pathway with the disease risk, for the SNPs
associated with a pathway, the cases will be similar to
other cases than to controls. This method provides a
new analytical tool that could enrich the power of
GWAS in BC risk prediction (Braun and Buetow, 2011).
In conclusion, the recently discovered data could open
up new streets for basic research. In future, a new
GWAS in breast cancer
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generation of large-scale association studies, in combi-
nation with replication analyses and multiple scans
could be able to identify many more loci.
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